Coronaios: Remdesivir does not work well, says WHO – Which drug increases the chance of survival



Remedisivir treatment has no significant effect on a Covid-19 patient’s chances of survival or hospitalization, according to the World Health Organization (WHO) Large Clinical Study, which has raised frustrations, as many have high hopes. The study evaluated remedisivir and three other drugs in 11,266 patients in more than 500 hospitals in 30 countries, finding that no treatment “substantially affects mortality” or intubation, according to the Financial Times. “Treatments with remedesivir, hydroxychloroquine, lopinavir and interferon have been shown to have little effect on in-hospital mortality,” according to the study. The remedisivir-specific arm included 2,750 patients who were given the drug for ten days (200 milligrams on the first day and 100 milligrams on the following day). Which drug works? WHO findings mean that it is currently the only drug that proves increased The chance of survival from Covid-19 is dexamethasone, a cheap steroid that is taken orally and is widely available internationally. The WHO has recommended the use of steroids in severe cases of Covid-19. The agency now hopes for monoclonal antibodies, immunomodulatory and other antiviral drugs. Remdesivir was originally developed by the American drug company Gilead Sciences as a drug against the Ebola virus. It was one of the drugs recently administered to US President Donald Trump. The company recently entered into an agreement with the EU for the initial supply of up to 500,000 doses of the drug in European countries, with the possibility of a new supply in the future. The results of the study were posted as a pre-publication on medRxiv. (Link for scientific pre-publication: https: / /www.medrxiv.org/content/10.1101/2020.10.15.20209817v1) Source: ΑΠΕ-ΜΠΕ



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *